Skip to main content
. 2020 Jun 25;68(7):1424–1431. doi: 10.4103/ijo.IJO_1612_19

Table 3.

Antibiotics resistance report

Cluster No. of patients No. of samples tested AK GEN TOB CIP GAT OF MO C CAZ CTR IPM MRP PI CL
1 (Dec 2006) 4 4 2 (50) 3 (75) 4 (100) 0 1 (25) 1 (25) NT 4 (100) 3 (75) NT NT NT NT NT
2 (Sep 2011) 2 2 2 (100) NT 0 NT 2 (100) NT 2 (100) 2 (100) 2 (100) 2 (100) 0 NT NT 2 (100)
3 (Oct 2011) 4 3 3 (100) NT 2 (66.6) 3 (100) 3 (100) NT NT 3 (100) 3 (100) 3 (100) 2 (66.6) NT NT 0
4 (Mar 2012) 9 9 9 (100) 9 (100) 9 (100) 9 (100) 9 (100) 9 (100) 9 (100) 9 (100) 9 (100) 9 (100) 0 NT NT 0
5 (Dec 2012) 13 11 0 11 (100) 11 (100) 11 (100) 11 (100) 11 (100) 11 (100) 1 (9.09) 11 (100) 11 (100) 0 NT 5 (45.4) 0
6 (Mar 2018) 30 11 11 (100) 11 (100) 11 (100) 11 (100) 11 (100) 11 (100) 11 (100) 11 (100) 0 4 (36.3) 11 (100) 9 (81.8) 2 (18.1) 1 (9.09)
Overall Resistance 27 (67.5) 34 (97.1) 37 (92.5) 34 (89.4) 37 (92.5) 32 (91.4) 33 (100) 30 (75) 28 (70) 29 (80.5) 13 (36.1) 9 (81.8) 7 (31.8) 3 (8.3)

AK=Amikacin, GEN=Gentamicin, TOB=Tobramycin, CIP=Ciprofloxacin, GAT=Gatifloxacin, OF=Ofloxacin, MO=Moxifloxacin, C=Chloramphenicol, CAZ=Ceftazidime, CTR=Ceftriaxone, IPM=Imipenem, MRP=Meropenem, PI=Piperacillin, COL=Colistin, NT=Not tested. Numbers in bracket indicates percentage